About BioMonde
BioMonde is a company based in Gainesville (United States) founded in 2014. BioMonde has raised $5.9 million across 1 funding round from investors including Oxford Capital and Development Bank of Wales. BioMonde offers products and services including BioBag and Larval Therapy. BioMonde operates in a competitive market with competitors including Tenaya Therapeutics, Orca Bio, Athira Pharma, Histogenics and Organogenesis, among others.
- Headquarter Gainesville, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biomonde Ltd.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5.9 M (USD)
in 1 rounds
-
Latest Funding Round
$5.9 M (USD), Series A
Jun 02, 2014
-
Investors
Oxford Capital
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of BioMonde
BioMonde offers a comprehensive portfolio of products and services, including BioBag and Larval Therapy.
Net dressing containing larvae for effective wound debridement.
Natural treatment for rapid and selective wound bed preparation.
Funding Insights of BioMonde
BioMonde has successfully raised a total of $5.9M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.9 million completed in June 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in BioMonde
BioMonde has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Oxford Capital and Development Bank of Wales.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage venture capital is invested in UK technology sectors.
|
Locked | Locked | Locked | |
|
Sustainable business finance is provided for companies in Wales.
|
Locked | Locked | Locked |
Investor details for BioMonde
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioMonde
Investment portfolio details for BioMonde
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BioMonde
Detailed financials for BioMonde
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biomonde Comparisons
Peer comparison for BioMonde
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BioMonde
BioMonde operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Orca Bio, Athira Pharma, Histogenics and Organogenesis, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapeutics, including for Alzheimer’s and Parkinson’s, are developed.
|
|
| Locked | Locked | Locked |
Restorative cell therapies for orthopedic diseases are developed.
|
|
| Locked | Locked | Locked |
Regenerative therapies for wound care are developed and commercialized.
|
|
| Locked | Locked | Locked |
Engineered cell and gene therapies are developed for multiple diseases.
|
Detailed competitors of BioMonde
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biomonde
Complete news archive for BioMonde
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioMonde
BioMonde was founded in 2014.
BioMonde is headquartered in Gainesville, United States.
BioMonde is a funded company, having raised a total of $5.9M across 1 funding round to date.
BioMonde was founded in 2014 and is based in Gainesville, United States, within the medical devices sector. Larva therapy products, including the BioBag device, are produced using an aseptic process involving greenbottle fly larvae. These are supplied for debridement of wounds such as pressure ulcers, diabetic ulcers, venous stasis ulcers, and surgical or traumatic injuries. Operations occur in a specialized manufacturing facility.
BioMonde's top competitors include Tenaya Therapeutics, Athira Pharma and Orca Bio.
BioMonde offers BioBag and Larval Therapy.
BioMonde has 2 investors. Key investors include Oxford Capital, and Development Bank of Wales.